Our partners
Ekalia: deploying an international network of industrial-scale Astatine-211 (²¹¹At) production sites close to customers
Goal
The Ekalia JV is dedicated to deploying an international network of industrial-scale Astatine-211 (²¹¹At) production sites close to customers, making this promising radioisotope available for future targeted cancer therapies. Jointly owned by the two partners, the new company combines IBA’s cutting-edge cyclotron and isotope production technologies with Framatome’s nuclear industrial expertise. Together, the two companies intend to establish a network of production sites across Europe and North America.
Learn more about Ekalia
Read the Press Release about this new alliance between IBA and Framatome
Goal
The demand for Actinium-225 is rapidly increasing, driven by the expansion of Targeted Alpha Therapy (TAT) clinical pipelines and the rising number of alpha-emitting radiopharmaceuticals under investigation.
To meet this need, PanTera deployed a dual-pathway production strategy, combining an early supply solution by extracting Ac-225 from Thorium-229, with a commercial supply pathway by using its proprietary Radium-226 (226Ra) photonuclear production process. With this patented process, PanTera will be able to deliver industrial-scale volumes of high-purity Ac-225.
In October 2025, after obtaining all required nuclear and environmental permits, PanTera celebrated the groundbreaking of its Actinium Production Center (APC) in Belgium.
The Actinium Production Center will host PanTera’s unique Ra-226 irradiation process with high-energy gamma beam to generate Actinium-225 and secure reliable access to this crucial radioisotope.
The first commercial supply of Ac-225 is expected in 2029.
Supporting Cancer Care through European and National Research Collaboration
The project
IBA RadioPharma Solutions is actively contributing to the advancement of precision oncology and theranostics through its involvement in major European and National research initiatives. Among these, the IHI project Accelerate.EU and the Innovative Industrial Target Preparation (ITTP) program play a central role in strengthening the technological and production capabilities required for next-generation radiopharmaceuticals.
IHI project, Accelerate.EU : Elevating the future of cancer care with alpha theranostics
This IHI project, led by IBA and the Institute Jules Bordet, unites a consortium of 17 European partners. This initiative is pioneering the development of novel radiotheranostic pairs based on alpha-emitting radioisotope Astatine-211 (211At), with the objective of targeting aggressive cancers, such as pancreatic, breast, and brain cancers.
As the industry leader of this initiative, IBA is facilitating the development of a production network to enable greater access to targeted alpha therapy across Europe, through the development of a new alpha-machine cyclotron as an in-kind contribution.
Interested in Accelerate.EU
Read the latest updates about this IHI Project
ITTP : Revolutionize the manufacturing process to expand radiometals production capacity
Supported by the Walloon Region in Belgium, this ambitious €4.1 million project aims to improve the production of radioisotopes by developing innovative manufacturing processes for solid irradiation targets, with the ultimate goal of expanding radiometals production capacity.
The Innovative Industrial Target Preparation (ITTP) consortium includes 4 partners: ICS, University of Namur, University of Mons and IBA RadioPharma Solutions.
Accredited by the Mecatech cluster and co-certified with BioWin, it represents a remarkable opportunity to advance research in Belgium and strengthen its leadership in the field of nuclear medicine.